Emerging pharmacological therapies for fibromyalgia

Current Opinion in Investigational Drugs

Volumn 7, Issue 7, 2006, Pages 631-636

  Lawson, Kim ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Disordered sleep; Emerging therapies; Fatigue; Fibromyalgia; Pain; Randomized controlled trials

Indexed keywords

AD 337; AMITRIPTYLINE; DRONABINOL; DULOXETINE; EPLIVANSERIN; ESZOPICLONE; ETIRACETAM; FLUOXETINE; GABOXADOL; HYDROCORTISONE; HYPNOTIC SEDATIVE AGENT; IBUTAMOREN; INDIPLON; MILNACIPRAN; MOCLOBEMIDE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OXYBATE SODIUM; PARGYLINE; PRAMIPEXOLE; PREGABALIN; RADAFAXINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZONISAMIDE; ZOPICLONE;

ABDOMINAL PAIN; ANXIETY DISORDER; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC PAIN; CLINICAL TRIAL; COMA; CONSTIPATION; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; FIBROMYALGIA; FLUSHING; HEART PALPITATION; HUMAN; NAUSEA; PATHOPHYSIOLOGY; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SWEAT GLAND DISEASE; URINE INCONTINENCE; WEIGHT REDUCTION; XEROSTOMIA;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DOPAMINE AGONISTS; FIBROMYALGIA; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 33745770049     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P et al: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum (1990) 33(2):160-172.
2. White KP, Harth M: Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep (2001) 5(4):320-329.
3. Crofford LJ, Clauw DJ: Fibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum (2002) 46(5):1136-1138.
4. Henriksson KG: Hypersensitivity in muscle pain syndromes. Curr Pain Headache Rep (2003) 7(6):426-432.
5. Arendt-Nielsen L, Graven-Nielsen T: Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep (2003) 7(5):355-361.
6. Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ: Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain (2004) 110(3):689-696.
7. Bennett R: Fibromyalgia: Present to future. Curr Rheumatology Rep (2005) 7(5):371-376.
8. Martinez-Lavin M: Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep (2004) 8(5):385-389.
9. Kelemen J, Lang E, Balint G, Trocsanyi M, Muller W: Orthostatic sympathetic derangement of baroreflex in patients with fibromyalgia. J Rheumatol (1998) 25(4):823-825.
10. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H: Dysautonomia among patients with fibromyalgia: A noninvasive assessment. J Rheumatol (2000) 27(11):2660-2665.
11. Baker K, Barkhuizen A: Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep (2005) 9(5):301-306.
12. Mease P: Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl (2005) 75:6-21.
13. Offenbaecher M, Ackenheil M: Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS Spectrums (2005) 10(4):285-297.
14. Rao SG, Clauw DJ: The management of fibromyalgia. Drugs Today (2004) 40(6):539-554.
15. Crofford LJ: Pharmaceutical treatment options for fibromyalgia. Curr Rheumatology Rep (2004) 6(4):274-280.
16. Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum (2005) 52(5):1577-1584.
17. Lawson K: Tricyclic antidepressants and fibromyalgia: What is the mechanism of action? Expert Opin Invest Drugs (2002) 11(10):1437-1445.
18. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum (2004) 50(9):2974-2984.
19. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain (2005) 119(1-3):5-15.
20. Stahl SM, Grady MM, Moret C, Briley M: SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums (2005) 10(9):732-747.
21. Shuto S, Takada H, Mochizuki D, Tsujita R, Hase Y, Ono S, Shibuya N, Matsuda A: (+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists. J Med Chem (1995) 38(15):2964-2968.
22. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG: A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol (2004) 19(Suppl 1):S27-S35.
23. Gendreau RM, Thom MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Meese PJ, McLean SA, Clauw DJ: Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol (2005) 32(10):1975-1985.
24. Compounds in trial - milnacipran phase III: Cypress Bioscience Inc, San Diego, CA, USA (2006). http://www.cypressbio.com/products/milnacipranPhase3.php
25. Forest Laboratories Inc/Cypress Bioscience Inc: Forest Laboratories Inc and Cypress Bioscience Inc to commence third milnacipran phase III trial. Press Release (2006) January 05.
26. Zijlstra TR, Barendregt PJ, van De Laar MAF: Venlafaxine in fibromyalgia: Results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum (2002) 46:S105.
27. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P: A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol (1998) 37(12):1279-1286.
28. Nicolodi M, Sicuteri F: Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol (1996) 398:373-379.
29. GlaxoSmithKline: Annual Report 2005. (2006): March 03.
30. AD 337 - pipeline: Sosei Co Ltd, Tokyo, Japan (2006). http://www.sosei.com/en/pipeline/337.html
31. Gronblad M, Nykanen J, Konttinen Y, Jarvinen E, Helve T: Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol (1993) 12(2):186-191.
32. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ: The effect of zolpidem in patients with fibromyalgia: A dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol (1996) 23(3):529-533.
33. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T: Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep (2003) 26(7):793-799.
34. Scharf M: Eszopiclone for the treatment of insomnia. Expert Opin Pharmacother (2006) 7(3):345-356.
35. Xyrem International Study Group: Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: A double-blind, placebo-controlled study in 228 patients. Sleep Med (2005) 6(5):415-421.
36. Russell IJ, Bennett RM, Michalek JE, Oxybate for FMS Study Group: Orally-administered sodium oxybate [GHB] relieves pain and improves sleep in patients with fibromyalgia syndrome [FMS]: A randomized, double-blind, placebo-controlled, multi-center clinical trial. Annual Meeting of the American College of Rheumatology (2005):Abs L30.
37. Scharf MB, Baumann M, Berkowitz DV: The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol (2003) 30(5):1070-1074.
38. Wilson S, Argyropoulos S: Antidepressants and sleep: A qualitative review of the literature. Drugs (2005) 65(7):927-947.
39. sanofi-aventis: Annual Report 2004. http://en.sanofi-aventis.com/images/050418_ar2004_en_tcm24-2539.pdf
40. Blackburn-Munro G, Erichsen HK: Antiepileptics and the treatment of neuropathic pain: Evidence from animal models. Curr Pharm Design (2005) 11(23):2961-2976.
41. 3H]-norepinephrine release from rat neocortical slices. Synapse (2002) 45(3):171-190.
42. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology (2002) 42(2):229-236.
43. 2-δ type 1 genetically modified mice. Brain Res (2006) 1075(1):68-80.
44. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U: Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 52(4):1264-1273.
45. Dworkin R, Sharma U, Stacey B, Chambers R, Siffert J: Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. 24th American Pain Society Meeting Boston, MA, USA (2005):Abs 686.
46. Holman AJ, Myers RR: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum (2005) 52(8):2495-2505.
47. Holman AJ: Treatment of fibromyalgia with the dopamine agonist ropinirole: A 14-week double-blind pilot randomized controlled trial with 14-week blinded extension. Annual Meeting of the American College of Rheumatology San Antonio, TX, USA (2004):Abs L9.
48. Russo EB: Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett (2004) 25(1-2):31-39.
49. Schelling G, de Quervain D, Wichnalek M, Beyer A: Low-dose hydrocortisone for fibromyalgia - preliminary results from an ongoing randomized trial. NIH Sponsored Fibromyalgia Meeting, Washington, DC, USA (2004).
50. ClinicalTrials.gov: Supporting effect of dronabinol on behavioral therapy in fibromyalgia and chronic back pain. (2005). http://www.clinicaltrials.gov/ct/show/NCT00176163?order=24
51. ClinicalTrials.gov: GW679769 in fibromyalgia. (2006). http://www.clinicaltrials.gov/ct/show/NCT00264628?order=10
52. ClinicalTrials.gov: Efficacy study of low-dose hydrocortisone treatment for fibromyalgia. (2005). http://www.clinicaltrials.gov/ct/gui/show/NCT00236925
53. ClinicalTrials.gov: Efficacy and safety of an oral growth hormone drug in the treatment of fibromyalgia. (2005). http://www.clinicaltrials.gov/ct/show/NCT00116129?order=4
54. ClinicalTrials.gov: Levetiracetam for treatment of pain associated with fibromyalgia. (2005). http://www.clinicaltrials.gov/ct/show/NCT00254657.
55. ISRCTN Register: A randomised, placebo-controlled, rising dose, crossover study to evaluate the effectiveness of modafinil in the management of fatigue in fibromyalgia. (2005). http://www.controlled-trials.com/isrctn/trial/FIBROMYALGIA/0/ 34021674.html
56. ISRCTN Register: Moxonidine for the treatment of fibromyalgia: A prospective double-blind, randomized, single-center, placebo-controlled, parallel group study. (2005). http://www.controlled-trials.com/isrctn/trial/FIBROMYALGIA/0/ 70535562.html
57. ClinicalTrials.gov: A trial assessing the effect of nabilone on pain and quality of life in patients with fibromyalgia. (2006). http://www.clinicaltrials.gov/ct/show/NCT00272207?order=11
58. ClinicalTrials.gov: Zonisamide for fibromyalgia & migraine. (2005). http://www.clinicaltrials.gov/ct/show/NCT00259636?order=26